Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.

被引：5

作者：

Itzykson, Raphael ^{[1
]}

Thepot, Sylvain ^{[1
]}

Recher, Christian ^{[2
]}

Delaunay, Jacques ^{[3
]}

Quesnel, Bruno ^{[4
]}

Dreyfus, Francois ^{[5
]}

Koka, Anne Marfaing ^{[6
]}

Vey, Norbert ^{[7
]}

Stamatoullas, Aspasia ^{[8
]}

Gyan, Emmanuel ^{[9
]}

Cluzeau, Thomas ^{[10
]}

Rousselot, Philippe ^{[11
]}

Reman, Oumedaly ^{[12
]}

Plantier, Isabelle ^{[13
]}

Marolleau, Jean Pierre ^{[14
]}

More, Pierre ^{[15
]}

Wattel, Eric ^{[16
]}

Visanica, Sorin ^{[17
]}

Zerhouni, Chahinez ^{[1
]}

Bordessoule, Dominique ^{[18
]}

Ades, Lionel

Fenaux, Pierre ^{[19
,20
]}

Gardin, Claude

机构：

[1] GFM, Bobigny, France

[2] CHU Purpan, Toulouse, France

[3] CHU Nantes, F-44035 Nantes 01, France

[4] CHRU, Lille, France

[5] Hop Cochin, AP HP, F-75674 Paris, France

[6] Hop Antoine Beclere, AP HP, Clamart, France

[7] Inst J Paoli I Calmettes, F-13009 Marseille, France

[8] Ctr Henri Becquerel, F-76038 Rouen, France

[9] CHU Tours, Tours, France

[10] CHU, Nice, France

[11] CH, Versailles, France

[12] CHU Caen, F-14000 Caen, France

[13] CH, Roubaix, France

[14] CHU, Amiens, France

[15] CH, Lens, France

[16] Hop Edouard Herriot, Lyon, France

[17] CHR, Metz, France

[18] CHU, Limoges, France

[19] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France

[20] Inst Gustave Roussy, INSERM 848, Bobigny, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.843.843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：436 / 436

页数：1

共 50 条

[41] Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory acute myeloid leukaemia: Results of the UK Medical Research Council AML-R trial.
Yin, JAL
Wheatley, K
Rees, J
Burnett, A
BLOOD, 1998, 92 (10) : 231A - 231A
[42] Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.
Ades, Lionel
Stamatoullas, Aspasia
Raffoux, Emmanuel
Prebet, Thomas
Lenain, Pascal
Guieze, Romain
Hunault, Mathilde
Wattel, Eric
Stalnikiewicz, Laurence
Bouabdallah, Krimo
Levy, Vincent
Vey, Norbert
Dombret, Herve
Boehrer, Simone
Gardin, Claude
Fenaux, Pierre
BLOOD, 2009, 114 (22) : 434 - 434
[43] CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial
Roboz, Gail J.
Ravandi, Farhad
Wei, Andrew H.
Dombret, Herve
Dohner, Hartmut
Thol, Felicitas
Voso, Maria Teresa
Schuh, Andre C.
Porkka, Kimmo
La Torre, Ignazia
Skikne, Barry
Kumar, Keshava
Dong, Qian
Beach, C. L.
Risueno, Alberto
De Menezes, Daniel Lopes
Ossenkoppele, Gert
BLOOD, 2020, 136
[44] Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial
Yin, JAL
Wheatley, K
Rees, JKH
Burnett, AK
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 713 - 726
[45] Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
Ravandi, Farhad
Wei, Andrew H.
Doehner, Hartmut
Sayar, Hamid
Montesinos, Pau
Dombret, Herve
Selleslag, Dominik
Porkka, Kimmo
Jang, Jun Ho
Skikne, Barry
Beach, C. L.
Tian, Yu
Roboz, Gail J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S252 - S253
[46] Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukaemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
Wei, Andrew
Doehner, Hartmut
Sayar, Hamid
Ravandi, Farhad
Montesinos, Pau
Dombret, Herve
Selleslag, Dominik
Porkka, Kimmo
Jang, Jun Ho
Skikne, Barry
Beach, C. L.
Tian, Yu
Chevassut, Timothy
Roboz, Gail
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 54 - 55
[47] Superiority of autologous over allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after intensive chemotherapy
Thomas, X
Le, QH
Fenaux, P
Dombret, H
Chelghoum, Y
Pautas, C
Dreyfus, F
Stamatoullas, A
Dhedin, N
Troncy, J
Pigneux, A
Thiebaut, A
Elhamri, M
Michallet, M
BONE MARROW TRANSPLANTATION, 2003, 31 : S172 - S172
[48] Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial'
Smith, BD
Karp, J
Burke, P
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) : 164 - 165
[49] Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial
Wei, Andrew H.
Döehner, Hartmut
Sayar, Hamid
Ravandi, Farhad
Montesinos, Pau
Dombret, Hervé
Selleslag, Dominik
Porkka, Kimmo
Jang, Jun Ho
Skikne, Barry
Beach, C. L.
Tian, Yu
Roboz, Gail J.
BLOOD, 2021, 138
[50] Pilot study of intensive chemotherapy followed by hematopoietic stem cells rescue (IC plus HCR) in patients with refractory or relapsed primary central nervous system lymphoma (PCNSL) or intraocular lymphoma (ICL)
Soussain, C
Hoang-Xuan, K
Azar, N
Suzan, F
Gerber, S
Delattre, JY
Leblond, V
NEUROLOGY, 1999, 52 (06) : A246 - A247

← 1 2 3 4 5 →